It's a real struggle to pierce the veil and figure out what...

It's a real struggle to pierce the veil and figure out what really is happening with this company. They've talked about the need to diversify for a long time now and thrown out plenty of options, perhaps too many, but they fail to see the frustrations of long-term holders who see everything stall and drag out forever and a day. Vitiligo has been on the cards as the logical follow on since I first invested in 2012 but only now do they sound serious about it and we have only a history of broken promises to keep the faith with. Surely they've engaged with multiple experts already?!?

Why isn't XP something they can't get more than a handful of people treated in what seems like years now!? Massive unmet need. Surely a desperate requirement exists and if the economics make no sense then those numbers should have been looked at before starting
So my two scenarios I see for this predicament are 1) trying to do things cheap and therefore slow. This fits reasonably well with the narrative from management but has the obvious issues of frustrating existing shareholders and giving competitors an edge chronologically. Also there's no drive to commit to something and build the necessary components that would enable proper execution. Seriously who in the company could really get an approved drug out there to a broader patient base?
Or 2) as mentioned above there's some kind of plan towards a future sale and the impetus to look after standard investors is minimal and it's only going to happen at a price that won't impress many long-term holders.
Of course there's always the other option that they have absolutely no idea what they're doing and are just making it up as they go whilst being very well remunerated. Hate to believe this one but of late I start to wonder